Joseph Stringer
Stock Analyst at Needham
(4.12)
# 470
Out of 5,161 analysts
299
Total ratings
48.23%
Success rate
13.9%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Joseph Stringer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IONS Ionis Pharmaceuticals | Maintains: Buy | $90 → $103 | $74.79 | +37.72% | 26 | Feb 26, 2026 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $148 → $139 | $90.02 | +54.41% | 30 | Feb 26, 2026 | |
| VIR Vir Biotechnology | Maintains: Buy | $14 → $18 | $9.82 | +83.30% | 20 | Feb 24, 2026 | |
| GILD Gilead Sciences | Reiterates: Buy | $170 | $146.00 | +16.44% | 11 | Feb 23, 2026 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $529 → $510 | $320.43 | +59.16% | 25 | Feb 12, 2026 | |
| APLS Apellis Pharmaceuticals | Maintains: Buy | $29 → $28 | $19.38 | +44.48% | 21 | Jan 13, 2026 | |
| PCVX Vaxcyte | Maintains: Buy | $90 → $110 | $57.53 | +91.20% | 18 | Jan 7, 2026 | |
| MRNA Moderna | Reiterates: Hold | n/a | $55.97 | - | 9 | Oct 20, 2025 | |
| STOK Stoke Therapeutics | Maintains: Buy | $22 → $35 | $37.94 | -7.75% | 24 | Oct 10, 2025 | |
| PHAT Phathom Pharmaceuticals | Maintains: Buy | $28 | $11.15 | +151.23% | 52 | Jun 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $11 | $6.03 | +82.42% | 19 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $492.38 | - | 6 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $1.72 | - | 13 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $10 | $1.33 | +651.88% | 17 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $37 | $21.97 | +68.41% | 6 | Jan 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $18 | $13.81 | +30.34% | 2 | Aug 24, 2021 |
Ionis Pharmaceuticals
Feb 26, 2026
Maintains: Buy
Price Target: $90 → $103
Current: $74.79
Upside: +37.72%
Rhythm Pharmaceuticals
Feb 26, 2026
Maintains: Buy
Price Target: $148 → $139
Current: $90.02
Upside: +54.41%
Vir Biotechnology
Feb 24, 2026
Maintains: Buy
Price Target: $14 → $18
Current: $9.82
Upside: +83.30%
Gilead Sciences
Feb 23, 2026
Reiterates: Buy
Price Target: $170
Current: $146.00
Upside: +16.44%
Alnylam Pharmaceuticals
Feb 12, 2026
Maintains: Buy
Price Target: $529 → $510
Current: $320.43
Upside: +59.16%
Apellis Pharmaceuticals
Jan 13, 2026
Maintains: Buy
Price Target: $29 → $28
Current: $19.38
Upside: +44.48%
Vaxcyte
Jan 7, 2026
Maintains: Buy
Price Target: $90 → $110
Current: $57.53
Upside: +91.20%
Moderna
Oct 20, 2025
Reiterates: Hold
Price Target: n/a
Current: $55.97
Upside: -
Stoke Therapeutics
Oct 10, 2025
Maintains: Buy
Price Target: $22 → $35
Current: $37.94
Upside: -7.75%
Phathom Pharmaceuticals
Jun 6, 2025
Maintains: Buy
Price Target: $28
Current: $11.15
Upside: +151.23%
May 13, 2025
Maintains: Buy
Price Target: $16 → $11
Current: $6.03
Upside: +82.42%
May 6, 2025
Reiterates: Hold
Price Target: n/a
Current: $492.38
Upside: -
Mar 7, 2025
Reiterates: Hold
Price Target: n/a
Current: $1.72
Upside: -
Mar 4, 2025
Downgrades: Hold
Price Target: $10
Current: $1.33
Upside: +651.88%
Jan 24, 2024
Upgrades: Buy
Price Target: $37
Current: $21.97
Upside: +68.41%
Aug 24, 2021
Maintains: Buy
Price Target: $32 → $18
Current: $13.81
Upside: +30.34%